Novo and Lilly just slashed prices on GLP-1 weight-loss drugs that recently cost over $1,000 a month. What happened?

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Eli Lilly stock soars on obesity drug success. See here to know why LLY remains a top pick with strong growth prospects and a ...

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

Lilly becomes the first pharmaceutical company to hit that threshold, joining a select club of mostly tech companies.

Eli Lilly said on Friday it plans to roll out an employer-focused obesity care model early next year, aiming to expand access ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the ...

The world’s largest drugmaker, Eli Lilly & Co., just notched another milestone: it’s the first health-care company to cross ...

Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, ...

Novo Nordisk announced on Monday that it is lowering costs for weight loss and diabetes drugs, weeks after it struck a deal ...